Scarica l'app Stockscreener
14.46
0.00%
0.00
Dopo l'orario di chiusura:
14.46
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Precedente Chiudi:
$14.46
Aprire:
$14.45
Volume 24 ore:
2.59M
Relative Volume:
0.57
Capitalizzazione di mercato:
$4.54B
Reddito:
$634.21M
Utile/perdita netta:
$-27.11M
Rapporto P/E:
-163.39
EPS:
-0.0885
Flusso di cassa netto:
$29.85M
1 W Prestazione:
+0.00%
1M Prestazione:
+0.21%
6M Prestazione:
+70.72%
1 anno Prestazione:
+115.50%
Intervallo 1D:
$14.45
$14.47
Intervallo di 1 settimana:
$14.45
$14.47
Portata 52W:
$5.51
$14.48
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Nome
Amicus Therapeutics Inc
Settore
Industria
Telefono
(609) 662-2000
Indirizzo
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
14.46 | 4.54B | 634.21M | -27.11M | 29.85M | -0.0885 |
VRTX
Vertex Pharmaceuticals Inc
|
436.59 | 111.71B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
747.36 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
805.38 | 51.89B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.43 | 41.49B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.31 | 35.31B | 5.36B | 287.73M | 924.18M | 2.5229 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-22 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-29 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-12-22 | Downgrade | TD Cowen | Buy → Hold |
| 2025-12-17 | Iniziato | Citigroup | Buy |
| 2025-09-18 | Aggiornamento | Needham | Hold → Buy |
| 2025-07-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Iniziato | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2024-05-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Ripresa | Goldman | Neutral |
| 2022-01-14 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Ripresa | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Hold |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2021-02-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Downgrade | Citigroup | Buy → Neutral |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-02-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-05 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2019-01-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Iniziato | Citigroup | Neutral |
| 2018-08-17 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
| 2017-09-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-08-10 | Reiterato | Chardan Capital Markets | Buy |
| 2017-01-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Iniziato | BofA/Merrill | Buy |
| 2016-04-14 | Iniziato | Robert W. Baird | Neutral |
| 2016-04-12 | Reiterato | Chardan Capital Markets | Buy |
| 2015-09-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
How Amicus Therapeutics Inc. (FOLD) Affects Rotational Strategy Timing - Stock Traders Daily
Amicus Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Amicus Therapeutics Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators - Markets Mojo
Amicus Therapeutics Hits New 52-Week High of $14.47 - Markets Mojo
Massachusetts Financial Services Co. MA Has $1.79 Million Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Share Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
Institution Moves: Can Amicus Therapeutics Inc expand its profit marginsEarnings Overview Summary & Capital Efficient Trading Techniques - baoquankhu1.vn
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates - ADVFN
How does Amicus Therapeutics Inc score in quality rankings2026 Biggest Moves & Community Shared Stock Ideas - baoquankhu1.vn
Patterns Watch: Will Amicus Therapeutics Inc benefit from geopolitical trendsPortfolio Gains Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
(FOLD) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Amicus Therapeutics Hits New 52-Week High of $14.48 - Markets Mojo
Panic Selling: Is Amicus Therapeutics Inc showing insider buyingWeekly Market Outlook & Daily Technical Forecast Reports - baoquankhu1.vn
Gap Down: Will Amicus Therapeutics Inc benefit from geopolitical trendsBuy Signal & Reliable Momentum Entry Alerts - baoquankhu1.vn
Will Amicus Therapeutics Inc benefit from geopolitical trends2026 Dividend Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
Amicus Therapeutics stock hits 52-week high at 14.46 USD By Investing.com - Investing.com Australia
Amicus Therapeutics stock hits 52-week high at 14.46 USD - Investing.com
FOLD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Amicus Therapeutics (NASDAQ:FOLD) Hits New 1-Year HighTime to Buy? - MarketBeat
BioMarin Pharmaceutical Secures European Regulatory Approval for Amicus Therapeutics Acquisition - marketscreener.com
EU Commission OKs BioMarin's Sole Acquisition of Amicus Therapeutics - marketscreener.com
Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Technical Analysis & Stock Price Forecast - intellectia.ai
Amicus Therapeutics stock hits 52-week high at $14.44 By Investing.com - Investing.com South Africa
Amicus Therapeutics stock hits 52-week high at $14.44 - Investing.com
EPS Watch: Is Amicus Therapeutics Inc in a bullish channelMarket Sentiment Report & Weekly High Return Stock Opportunities - baoquankhu1.vn
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year HighStill a Buy? - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total Return - Yahoo Finance
210,800 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by CIBRA Capital Ltd - MarketBeat
FOLD PE Ratio & Valuation, Is FOLD Overvalued - Intellectia AI
Recap Report: What is the long term forecast for Amicus Therapeutics Inc stockQuarterly Market Review & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Vanguard disaggregates holdings, reports 0% in Amicus (NASDAQ: FOLD) - Stock Titan
JPMorgan Chase & Co. Sells 94,105 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
ETFs investiert in Amicus Therapeutics, Inc.-Aktien - TradingView
Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion - MSN
Amicus Therapeutics Hits New 52-Week High of $14.43 - Markets Mojo
Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week HighWhat's Next? - MarketBeat
Amicus Therapeutics stock hits 52-week high at 14.39 USD By Investing.com - Investing.com Canada
Amicus Therapeutics stock hits 52-week high at 14.39 USD - Investing.com
Hudson Bay Capital Management LP Cuts Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics, Inc.(NasdaqGM: FOLD) dropped from NASDAQ Biotechnology Index - marketscreener.com
FOLD Should I Buy - Intellectia AI
872,411 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by Ion Asset Management Ltd. - MarketBeat
Iron Triangle Partners LP Takes Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin to acquire rare disease drug developer Amicus for $4.8B - MSN
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF Upside - Yahoo Finance
Amicus Therapeutics stock hits 52-week high at 14.38 USD By Investing.com - Investing.com Nigeria
Elevation Point Wealth Partners LLC Makes New Investment in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics Inc Azioni (FOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.66%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):